• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效

Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

作者信息

Cardesa-Salzmann Teresa Marta, Stephan Bernhard, Simon Arne, Furtwängler Rhoikos, Schöndorf Dominik, Heine Sabine, Torfah Eyad, Lux Margaux, Meyer Sonja, Graf Norbert

机构信息

Department of Pediatric Hematology & Oncology Universitätsklinikum des Saarlandes Homburg Germany.

Department of Hemostaseology and Transfusion Medicine Universitätsklinikum des Saarlandes Homburg Germany.

出版信息

Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.

DOI:10.1002/ccr3.5902
PMID:35600013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9122792/
Abstract

We report the case of a Jehovah's Witness adolescent patient with immune-mediated thrombotic thrombocytopenic purpura after SARS-Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach.

摘要

我们报告了一例感染新型冠状病毒2后发生免疫介导的血栓性血小板减少性紫癜的耶和华见证会青少年患者，该患者在未进行治疗性血浆置换（TPE）的情况下，使用卡泊单抗、皮质类固醇、利妥昔单抗和体外免疫吸附（EIA）成功治愈。对于无法选择TPE的其他患者，这种方法可能有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742f/9122792/6a184e2c65b9/CCR3-10-e05902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742f/9122792/6a184e2c65b9/CCR3-10-e05902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742f/9122792/6a184e2c65b9/CCR3-10-e05902-g001.jpg

相似文献

1
Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效
Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.
2
Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah's Witness patients: A review of reported cases.血栓性血小板减少性紫癜管理中对耶和华见证人患者的治疗方法：病例报告回顾。
Transfus Apher Sci. 2023 Aug;62(4):103706. doi: 10.1016/j.transci.2023.103706. Epub 2023 Mar 21.
3
Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.在一名耶和华见证会成员中成功管理血栓性血小板减少性紫癜且未进行血浆置换
J Clin Apher. 2015 Feb;30(1):46-9. doi: 10.1002/jca.21325. Epub 2014 Apr 30.
4
Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.一名耶和华见证会信徒在未使用血浆的情况下患血栓性血小板减少性紫癜的存活病例报告及文献综述
J Clin Apher. 2019 Oct;34(5):623-630. doi: 10.1002/jca.21710. Epub 2019 May 22.
5
Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.耶和华见证人中血栓性血小板减少性紫癜的成功管理：一种联合决策的个体化方法。
J Patient Exp. 2020 Feb;7(1):8-11. doi: 10.1177/2374373519829902. Epub 2019 Feb 14.
6
Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.成功治疗一名患有血栓性血小板减少性紫癜且不愿接受治疗性血浆置换的耶和华见证会成员。
J Clin Apher. 2007;22(6):330-2. doi: 10.1002/jca.20150.
7
Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.在一名耶和华见证人中使用卡泊单抗而非血浆置换治疗血栓性血小板减少性紫癜
Am J Ther. 2023;30(5):e502-e505. doi: 10.1097/MJT.0000000000001522. Epub 2022 May 26.
8
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.不进行血浆置换治疗血栓性血小板减少性紫癜：耶和华见证人的经验。
Blood Adv. 2017 Oct 30;1(24):2161-2165. doi: 10.1182/bloodadvances.2017012351. eCollection 2017 Nov 14.
9
Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.一名耶和华见证人因服用复方新诺明诱发血栓性血小板减少性紫癜
Am J Hematol. 2007 Jul;82(7):679-81. doi: 10.1002/ajh.20887.
10
Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.卡泊单抗第二疗程成功用于复发性血栓性血小板减少性紫癜
Platelets. 2022 Jul 4;33(5):790-791. doi: 10.1080/09537104.2021.1981851. Epub 2021 Sep 26.

引用本文的文献

1
Separate (Asynchronous) Therapeutic Plasma Exchange (TPE) and Plasma Transfusion in the Patient with Severe TPE Complications: A Case Report.重度治疗性血浆置换（TPE）并发症患者的单独（异步）治疗性血浆置换（TPE）与血浆输注：病例报告
Int J Hematol Oncol Stem Cell Res. 2025 Jan 1;19(1):75-80. doi: 10.18502/ijhoscr.v19i1.17827.

本文引用的文献

1
Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?迄今为止在新冠肺炎患者中报告的血栓性微血管病（非典型溶血尿毒综合征/免疫性血小板减少性紫癜）：是病毒单独导致的，还是多种机制和病因共同作用的结果？
Crit Rev Oncol Hematol. 2021 Jun;162:103347. doi: 10.1016/j.critrevonc.2021.103347. Epub 2021 May 1.
2
COVID 19 infection associated with thrombotic thrombocytopenic purpura.COVID-19 感染相关的血栓性血小板减少性紫癜。
J Thromb Thrombolysis. 2021 Aug;52(2):504-507. doi: 10.1007/s11239-021-02452-0. Epub 2021 Apr 27.
3
Thrombotic thrombocytopenic purpura associated with COVID-19 in a pediatric patient: case report.
一名儿科患者中与COVID-19相关的血栓性血小板减少性紫癜：病例报告
Hematol Transfus Cell Ther. 2021 Jul-Sep;43(3):349-352. doi: 10.1016/j.htct.2021.02.003. Epub 2021 Apr 8.
4
The SARS-CoV-2 as an instrumental trigger of autoimmunity.SARS-CoV-2 作为自身免疫的工具性触发因素。
Autoimmun Rev. 2021 Apr;20(4):102792. doi: 10.1016/j.autrev.2021.102792. Epub 2021 Feb 19.
5
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.血栓性血小板减少性紫癜：病理生理学、诊断与管理
J Clin Med. 2021 Feb 2;10(3):536. doi: 10.3390/jcm10030536.
6
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.卡泊西单抗治疗获得性血栓性血小板减少性紫癜的成本效益
Blood. 2021 Feb 18;137(7):969-976. doi: 10.1182/blood.2020006052.
7
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19.与新型冠状病毒肺炎相关的获得性血栓性血小板减少性紫癜的显著表现。
Haematologica. 2020 Oct 1;105(10):e540. doi: 10.3324/haematol.2020.262345.
8
Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.在卡普拉珠单抗治疗下，选择特定患者无需进行血浆置换治疗获得性血栓性血小板减少性紫癜。
J Thromb Haemost. 2020 Nov;18(11):3061-3066. doi: 10.1111/jth.15045. Epub 2020 Sep 6.
9
Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma.卡泊单抗用于治疗对新鲜冷冻血浆过敏患者的血栓性血小板减少性紫癜。
Transfusion. 2020 Aug;60(8):1666-1668. doi: 10.1111/trf.15823. Epub 2020 May 1.
10
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab.共同决策、血栓性血小板减少性紫癜与卡泊单抗
Am J Hematol. 2020 Apr;95(4):E76-E77. doi: 10.1002/ajh.25715. Epub 2020 Jan 14.